Open AccessFacing the Challenge of Post COVID-19 Pulmonary fibrosis: What is so unique about it?
Author(s) -
Medha Ghose,
Tasbirul Islam
Publication year - 2020
Publication title -
bangladesh critical care journal
Language(s) - English
Resource type - Journals
eISSN - 2307-7654
pISSN - 2304-0009
DOI - 10.3329/bccj.v8i2.50028
Subject(s) - medicine , ards , sequela , covid-19 , pulmonary fibrosis , pandemic , complication , fibrosis , intensive care medicine , lung , surgery , pathology , disease , outbreak , infectious disease (medical specialty)
COVID-19 pandemic is the highlight of the 21st century that took drastic effects on humanity. Over 23 million confirm infected with the majority with mild infection. However, over 62,000 cases are in critical condition with varying degrees of ARDS. A potential complication of severe ARDS could be Post COVID-19 Pulmonary fibrosis. Possible use of biomarkers to detect progression to fibrosis, along with prompt treatment of acute lung injury caused by COVID-19 and administration anti-fibrotic therapies, could be the next best method to treat this permanent and devastating sequela of COVID-19.
Bangladesh Crit Care J September 2020; 8(2): 102-107